These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19030742)

  • 21. Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil.
    Papi L; Menezes AC; Rocha H; Abreu TF; Oliveira RH; Frota AC; Evangelista Lde A; Hofer CB
    Braz J Infect Dis; 2014; 18(4):394-9. PubMed ID: 24794884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.
    Sánchez Torres AM; Munoz Muniz R; Madero R; Borque C; García-Miguel MJ; De José Gómez MI
    Eur J Pediatr; 2005 May; 164(5):271-6. PubMed ID: 15650834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
    Ocampo A; Domingo P; Fernández P; Diz J; Barberá JR; Sepúlveda MA; Salgado X; Rodriguez M; Santos J; Yzusqui M; Mayorga MI; Lorenzo JF; Bahamonde A; Bachiller P; Martínez E; Rozas N; Torres C; Muñoz A; Casado A; Podzamczer D
    J Antimicrob Chemother; 2018 Aug; 73(8):2171-2176. PubMed ID: 29788066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.
    Terry L; Sprinz E; Stein R; Medeiros NB; Oliveira J; Ribeiro JP
    Med Sci Sports Exerc; 2006 Mar; 38(3):411-7. PubMed ID: 16540826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
    Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
    HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy.
    Addy CL; Gavrila A; Tsiodras S; Brodovicz K; Karchmer AW; Mantzoros CS
    J Clin Endocrinol Metab; 2003 Feb; 88(2):627-36. PubMed ID: 12574192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.
    Hatano H; Miller KD; Yoder CP; Yanovski JA; Sebring NG; Jones EC; Davey RT
    AIDS; 2000 Sep; 14(13):1935-42. PubMed ID: 10997397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipid profile changes by high activity anti-retroviral therapy.
    Duro M; Sarmento-Castro R; Almeida C; Medeiros R; Rebelo I
    Clin Biochem; 2013 Jun; 46(9):740-4. PubMed ID: 23295258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
    Hiransuthikul N; Hiransuthikul P; Kanasook Y
    Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy.
    Walmsley S; Cheung AM; Fantus G; Gough K; Smaill F; Azad ; Diong C; Raboud J
    HIV Clin Trials; 2008; 9(5):314-23. PubMed ID: 18977720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Lipodystrophy in HIV infected children].
    Popielska J; Marczyńska M
    Med Wieku Rozwoj; 2004; 8(4 Pt 1):936-48. PubMed ID: 15951613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between lipodystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal.
    Alikhani A; Morin H; Matte S; Alikhani P; Tremblay C; Durand M
    BMC Infect Dis; 2019 Sep; 19(1):820. PubMed ID: 31533648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity.
    Villarroya F; Domingo P; Giralt M
    Trends Pharmacol Sci; 2005 Feb; 26(2):88-93. PubMed ID: 15681026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.
    Feldt T; Oette M; Kroidl A; Goebels K; Fritzen R; Kambergs J; Kappert G; Vogt C; Wettstein M; Häussinger D
    Infection; 2006 Apr; 34(2):55-61. PubMed ID: 16703293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic abnormalities in human immunodeficiency virus-infected children: two-year follow-up.
    Krause JC; Toye MP; Fisher DJ; Stechenberg BW; Reiter EO; Allen HF
    J Pediatr Endocrinol Metab; 2009 Apr; 22(4):345-51. PubMed ID: 19554809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.
    Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA
    Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.